Fenticonazole

Summary

Fenticonazole (CHEMBL1651990) is an approved small molecule (ATC D01AC12).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC12 (+1 more)
• Chemistry: 455.4 Da · C24H20Cl2N2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1651990
Name	Fenticonazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	51755
ChEBI	CHEBI:83602
ATC	D01AC12, G01AF12
Molecular formula	C24H20Cl2N2OS
Molecular weight	455.4
InChIKey	ZCJYUTQZBAIHBS-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)SC2=CC=C(C=C2)COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl

IUPAC name: 1-[2-(2,4-dichlorophenyl)-2-[(4-phenylsulfanylphenyl)methoxy]ethyl]imidazole

ChEBI definition: A member of the class of imidazoles that carries a 2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl group at position 1.

Also known as: Fenticonazol, Fenticonazole, SID170466486, FENTICONAZOLE, Fenticonazole nitrate, fenticonazole

Parent form; salt/anhydrous children: CHEMBL2107703

Patent coverage: 2,277 distinct patent families (8,940 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,873 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Alpha-2B adrenergic receptor, Progesterone receptor, Cannabinoid receptor 1, Motilin receptor, Sodium-dependent noradrenaline transporter, Type-1 angiotensin II receptor, Sodium-dependent serotonin transporter, D(3) dopamine receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 21 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CNR1	5.89	AC50	1300	nM	CHEMBL_ACT_25231188
KCNH2	5.84	AC50	1450	nM	CHEMBL_ACT_25118774
OPRK1	5.6	AC50	2500	nM	CHEMBL_ACT_25130006
NR1I2	5.42	AC50	3800	nM	CHEMBL_ACT_25224645
NR1I2	5.37	AC50	4300	nM	CHEMBL_ACT_25188624
ADORA3	5.19	AC50	6400	nM	CHEMBL_ACT_25134835
SLC6A4	5	AC50	9900	nM	CHEMBL_ACT_25150947

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).